Could a ketone drink boost CAR-T success in lymphoma?

NCT ID NCT06610344

Recruiting now Disease control Sponsor: Abramson Cancer Center at Penn Medicine Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a ketone supplement (beta-hydroxybutyrate) is safe and tolerable for 5 adults with large B-cell lymphoma who are receiving standard CAR-T cell therapy. Researchers will also look at changes in gut bacteria and immune cells. The supplement is given as a drink before and during treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: R-1,3-Butanediol (a ketone supplement that converts to beta-hydroxybutyrate)
What this could lead to: If it works, this could point toward a way to improve gut health and immune function during CAR-T therapy for lymphoma.
What could go wrong: This is a very small, early feasibility study with only 5 participants, so results may not apply broadly. The supplement could cause side effects or show no benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LARGE B-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

large B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LARGE B-CELL LYMPHOMA

Contacts and locations

Locations

Abramson Cancer Center at University of Pennsylvania
RECRUITING

Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.